Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HS-110 demonstrated a broad activation of T-cell mediated immune response in cancer patients. Result is due any time now this month in November
Glta $$$
this could be any day in November now?
excellent video clip -HTBX providing Pfizer with their medicine to provide extra protction to COVID 19 patients
HTBX mentioned live on CBS. Huge exposure
"Heat Biologics in Research Triangle Park is also working on a vaccine to combine with one like Pfizer’s to generate a more robust immune response."
Youtube Heat Biologics on CBS
Heat Biologics mentioned in USA TODAY Special "America Recovers".
———> Link KingBio Twitter
Boy your in trouble....lol
Jeff denied your statement and thats a serious sec violation if he indeed said anything like that!
State street corp took a starter investment today.
Isnt that cramers fund?
UBS and montreal bank too...
I just spoke to the CEO yesterday and he told me that he never said any such thing to any investor. He said that it would have been a serious SEC violation if he did. He said it never happened. He said don't believe everything you read unless it comes directly from the company.
Wrong! There is no dilution coming. HTBX is going up.
I actually requested this post to be removed. Not sure why it is still.posted. a mod can remove it with my permission
Big Advances in Knowledge begin with one Person;
thus it is with the potential Covid-19 antibody vaccine, offered by Pfizer-
requiring special handling, and limited in duration.
https://finance.yahoo.com/news/covid-19-vaccine-biontech-pfizer-partner-german-company-103909085.html
NEWS -- Heat Biologics Provides Third Quarter 2020 Business Update
Continued progress on oncology and COVID-19 vaccine programs
Over $117 million of cash and short-term investments
DURHAM, NC / ACCESSWIRE / November 9, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the third quarter ended September 30, 2020.
Jeff Wolf, Chief Executive Officer of Heat, commented, "We continue to make progress on both our oncology and COVID-19 vaccine programs. We presented data for HS-110 in combination with Nivolumab in our Phase 2 lung cancer trial at the 2020 American Society of Clinical Oncology Annual Meeting demonstrating a strong survival benefit in a cohort of previously treated checkpoint inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC). We are actively pursuing a variety of strategies to maximize value for the program."
"At the same time, we continue to advance PTX-35, our potential first-in-class T-cell co-stimulatory antibody, through clinical development. Earlier this year, we initiated the first clinical trial site for PTX-35 in multiple solid tumors and began dosing patients in the Phase 1 clinical trial. PTX-35 is designed to harness the body's natural antigen specific immune activation and tolerance mechanisms to reprogram immunity and provide a long-term, durable clinical effect. This study is expected to enroll up to 30 patients with advanced solid tumors refractory to standard of care."
"Importantly, we announced preclinical data for our gp96-based COVID-19 vaccine. The data, generated at the University of Miami Miller School of Medicine and published in bioRxiv, shows robust T-cell mediated immune response directed against the spike protein of SARS-CoV-2. Our gp96-based COVID-19 vaccine induced the expansion of both "killer" CD8+ T-cells that destroy virus infected cells, as well as "helper" CD4+ T-cells that assist in producing highly specific antibodies. As a result, we believe our vaccine has the potential to be used as either a standalone vaccine, or in combination with other antibody-focused vaccine approaches to enhance prophylactic protection. These results highlight the potential utility and versatility of our vaccine platform to address SARS-CoV-2, relevant mutations and other pathogens of interest."
"We continue to strengthen our IP portfolio and were recently awarded an additional U.S. patent covering Heat's gp96 platform in combination with a T cell costimulatory agonist in a single therapy. We believe the combination of our gp96 platform in a single therapy holds enormous promise in the prevention and treatment of cancer and infectious diseases, such as COVID-19."
"Finally, we have maintained a solid balance sheet with over $117 million of cash and short-term investments as of September 30, 2020. We believe this capital will provide us significant runway to achieve a number of important clinical milestones that we believe will drive value for shareholders in the months and years ahead," concluded Mr. Wolf.
Third Quarter 2020 Financial Results
Yup, that would be illegal, and a CEO would go do jail for saying all of that stuff over the telephone to a shareholder. That may be his first post here too. He also seems to claim that he talks to CEOs frequently. Just a trouble maker.
That would be illegal indirect insider trading lol
I just spoke to CEO 5 minutes ago and he stated the employees have been given the clear to sell. Also he said the demand for products are well below their expectations. He also stated that dilution is needed and expected to continue. Also that HTBX must face the facts of doing RS to keep them afloat Sad but true
Massive dilution coming.
The news prolly was that Hutchins was leaving
Can only follow what others say obviously the election is overriding everything
Nov 3rd is here and leaving. No news.
Breakout Setups Covid Plays:
$VTGN .68
$HTBX $1.15
Vaccine Predictions by Major Pharma haven't come true:
(Here's the correct link- the earlier one cut short.)
https://www.msn.com/en-us/health/medical/covid-19-vaccines-already-pharmaceutical-companies-predictions-havent-come-true/ar-BB1axDrT?li=BBnb7Kz
C'mon Uncle Sam, fund HTBX!
Vaccine predictions by major pharma haven't come true:
https://www.msn.com/en-us/health/medical/already-pharmaceutical-companies-predictions
C.mon Uncle Sam, fund HTBX !
Supposed to be some big announcement nov 3 rd you ll prob see this move later today in after hours then Monday Tuesday
So why this stock is not up???
Coronavirus antibodies decline over time in English study of 365,000 people done over this summer:
https://www.msn.com/en-us/health/medical/coronavirus-antibodies-decline-after-infection-study-finds-raising-questions-about-herd-immunity/ar-BB1aqOpK?ocid=msedgntp
It would seem, then, that the approach of Heat Biologics, of a T-Cell activating vaccine for Covid-19, could be the best solution thought of, to tame the pandemic, in my opinion.
Nice Covid set ups for HTBX T cell 's come on Wolf throw us a bone.
& VTGN Anxiety and Depression meds no side effects fast acting.
$HTBX
While discussing the CV, our President placed emphasis on the importance of immune health during his Wisconsin rally over the weekend. He wants to open the economy while protecting those with weakened immune systems.
This bodes well for stocks like HTBX.
...200 Million dollars in the bank...? I can't find this number anywhere? Do you have a link?
T cells companies HTBX & PDSB on watch Breakouts imminent.
RSI is about 40 for both.
$PDSB
I would think it cost a lot of money do study and make drugs lol
my bad they already sold these shares
they can sell for $100.000.000 shares
from time to time
If dilution is in play for real, this is to say that Jeff wolf is so greedy considering the company already has 200 Million dollars in the bank.
Im not either, but ENZC has so much upside potential, and I have some shares in it now. U may want to take a look at it. I have many shares in HEAT
* * $HTBX Video Chart 10-14-2020 * *
Link to Video - click here to watch the technical chart video
Heat just needs to get to the finish line before other drugs become the mainstream in hospitals. While a large handful of drugs will end up being in the basket of treatments that doctors can choose from, nevertheless it is good to be one of the top 5 to the finish line.
I'm not into subpenny stocks (very much). Way too risky. Been there and done it.
You probably don’t like this because this is not sub penny stock. It should be and will be at minimum a $10 stock once they figure out all other antibody vaccines are no good. Many people will learn that HEAT T-cell vaccine is the best vaccine option in term of effectiveness and long lasting.
By the way, many people will prefer preventive over treatment. Some people will be negatively affected Including death before doctor can determine if any treatment will work on the affected individual. Not everyone will be admitted to the hospital right away if get affected. If you are COVID-19 infected and try to get in the hospital to get treatment, you will be turned away by any hospital and return only when you are dying.
Many of us prefer HEAT T cell vaccine
PPS of HEAT should be $1000 a share because it is a life saving vaccine.
FYI...from one of my trading subscriptions. HTBX is not of the list of seven though. No matter. The shift in mindset from vaccine to treatment is the point. Naturally only those who are darlings of the media get the attention (for now that is).
-----------------
Good evening -
Over the last few months, biotech stocks have been moving up and down as the world digests every crumb of news about the progress towards a Covid-19 vaccine. But it’s time to face reality.
There may not be the October surprise predicted by President Trump. Even the furthest vaccines down the road will likely only be completing late-stage trials by the end of October After that, there has to be a waiting period to test for side effects.
In short, it’s important to get this right. And that’s the way it should be. Operation Warp Speed was never about shortcutting science. It was geared to speeding up production when a vaccine is available.
But that doesn’t mean 2021 will be a year-long version of Groundhog’s Day.
If there’s anything that President Trump’s treatment has shown investors, it’s that biotech companies may be further down the road towards producing proven antiviral therapies for the novel coronavirus.
Leaving the political issues aside, when experimental therapeutics are used (for now) successfully on a 74-year old, overweight man, that’s news.
While it’s far too early to say whether these drugs truly carry the answer, it does confirm what some have suspected from the beginning of the pandemic. That is that therapeutics, rather than a vaccine, maybe the ultimate solution to the coronavirus puzzle.
And as you might expect, dozens of companies are developing therapeutic treatments to mitigate the symptoms of infected patients. In this special presentation, we’re highlighting seven companies that you should be paying close attention to. If therapeutics nudge ahead of a vaccine, these stocks are likely to make strong upward moves.
After being pushed down by shorties and Flippers at 1.42, PPS is now going back up with a vengeance higher than 1.55.
It could go over 2 or 3 if they did not sell early
Paul
They have 200 million in the bank======
You do know that Heat has 50 million dollars in the bank.
All the big vaccine makers are having problems with vaccines. T cell protocols needed for a long lasting vaccine for Covid-19
T cell vaccine application players:
$PDSB
October Company Presentation:
https://www.pdsbiotech.com/images/pdf/presentation/2020/PDS_Biotech_Corporate_Presentation_-_OCTOBER_2020.pdf
https://www.pdsbiotech.com/
$HTBX
www.heatbio.com
HTBX October Presentation:
https://d1io3yog0oux5.cloudfront.net/_426f109437ac41f06a4cc3a2b6e430d8/heatbio/db/466/5424/pdf/Heat+Biologics+Corporate+Presentation+%28October+2020%29.pdf
HTBX 200 million market cap
PDSB 50 million market cap
$HTBX
Put bs took screen shot lol
Delisting after bankruptcy I think
COVID 19
OCTOBER 8, 2020
How Important Are T cells to the COVID-19 Immune Response?
https://www.clinicaloncology.com/COVID-19/Article/10-20/How-Important-Are-T-cells-to-the-COVID-19-Immune-Response-/60839
My two top T cell Vaccine companies.
PDSB 50 million market cap
HTBX 200 million market cap
$HTBX
That stock was at 4 dollars recently lost 75 percent not great feeling
“We are progressing with our Phase 1 trials with gp96 (HS-110) in combination with local OX40L (HS-130) and checkpoint inhibition as well as our gp96-based COVID-19 vaccine, and look forward to providing further clinical updates."
Followers
|
155
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6042
|
Created
|
01/26/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |